Combining forces: Study of the cytotoxic effect of the MDM2 inhibitor Nutlin-3 in combination with CDDP in non-small cell lung cancer cell lines

被引：0
|
作者：
Deben, C. [1 ]
Rolfo, C. [2 ]
Deschoolmeester, V. [1 ]
Wouters, A. [1 ]
Peeters, M. [3 ]
Gil-Bazo, I. [4 ]
Lardon, F. [1 ]
Pauwels, P. [5 ]
机构：
[1] Univ Antwerp, Oncol Res Ctr, B-2020 Antwerp, Belgium
[2] Univ Antwerp Hosp, Early Clin Trials Unit, Dept Oncol, Antwerp, Belgium
[3] Univ Antwerp Hosp, Dept Oncol, Antwerp, Belgium
[4] Univ Navarra Clin, Dept Oncol, Pamplona, Spain
[5] Univ Antwerp Hosp, Mol Pathol Unit, Dept Pathol, Antwerp, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70421-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
295
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [1] Preclinical study of the cytotoxic effect of nutlin-3a as monotherapy or in combination with gemcitabine in non-small cell lung cancer cell lines.
    Deben, Christophe
    Quix, Celine
    Wouters, An
    Baay, Marc
    Pauwels, Patrick
    Peeters, Marc
    Lardon, Filip
    Deschoolmeester, Vanessa
    CANCER RESEARCH, 2013, 73 (08)
  • [2] The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer
    Deben, Christophe
    Wouters, An
    Op de Beeck, Ken
    van den Bossche, Jolien
    Jacobs, Julie
    Zwaenepoel, Karen
    Peeters, Marc
    Van Meerbeeck, Jan
    Lardon, Filip
    Rolfo, Christian
    Deschoolmeester, Vanessa
    Pauwels, Patrick
    ONCOTARGET, 2015, 6 (26) : 22666 - 22679
  • [3] The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation
    Gasparini, Chiara
    Tommasini, Alberto
    Zauli, Giorgio
    HUMAN IMMUNOLOGY, 2012, 73 (04) : 342 - 345
  • [4] Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells
    Deben, Christophe
    Boullosa, Laurie Freire
    Domen, Andreas
    Wouters, An
    Cuypers, Bart
    Laukens, Kris
    Lardon, Filip
    Pauwels, Patrick
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 233 - 243
  • [5] Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation
    Mochizuki, Hiroyuki
    Goto-Koshino, Yuko
    Sato, Masahiko
    Fujino, Yasuhito
    Ohno, Koichi
    Tsujimoto, Hajime
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2012, 147 (3-4) : 187 - 194
  • [6] Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells
    Endo, Shinji
    Yamato, Kenji
    Hirai, Sachiko
    Moriwaki, Toshikazu
    Fukuda, Kuniaki
    Suzuki, Hideo
    Abei, Masato
    Nakagawa, Ichiro
    Hyodo, Ichinosuke
    CANCER SCIENCE, 2011, 102 (03) : 605 - 613
  • [7] MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma
    Tabe, Yoko
    Sebasigari, Denise
    Jin, Linhua
    Rudelius, Martina
    Davies-Hill, Theresa
    Miyake, Kazunori
    Miida, Takashi
    Pittaluga, Stefania
    Raffeld, Mark
    CLINICAL CANCER RESEARCH, 2009, 15 (03) : 933 - 942
  • [8] Mdm2 inhibitor nutlin-3 enhances the cytotoxic synergism induced by the combination of MEK1 inhibitor and arsenic trioxide (ATO) in AML cells.
    Lunghi, Paolo
    Mazzera, Laura
    Rizzoli, Vittorio
    Bonati, Antonio
    BLOOD, 2006, 108 (11) : 398A - 398A
  • [9] MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
    Ohnstad, Hege O.
    Paulsen, Erik B.
    Noordhuis, Paul
    Berg, Marianne
    Lothe, Ragnhild A.
    Vassilev, Lyubomir T.
    Myklebost, Ola
    BMC CANCER, 2011, 11
  • [10] MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
    Hege O Ohnstad
    Erik B Paulsen
    Paul Noordhuis
    Marianne Berg
    Ragnhild A Lothe
    Lyubomir T Vassilev
    Ola Myklebost
    BMC Cancer, 11
12345